Group 1 - The company Shenzhen Aishide Co., Ltd. received a notification from its shareholder Shenzhenshi Shenzhoutong Investment Group Co., Ltd. regarding the release of part of its pledged shares on September 5, 2025 [1][2] - The total number of shares released from pledge by Shenzhoutong Investment is 489,464,303 shares, which accounts for 39.50% of its holdings and 15.12% of the total share capital of the company [2][3] - As of the announcement date, the total pledged shares by the shareholder and its concerted parties amount to 609,954,734 shares, representing 49.22% of their total holdings [3][4] Group 2 - The controlling shareholder and its concerted parties have a pledged share ratio of 4.85%, which corresponds to a financing balance of 130 million yuan [3][4] - The total number of pledged shares due within one year is 115,270,000 shares, accounting for 18.90% of their holdings and 9.30% of the company's total share capital, with a financing balance of 410 million yuan [3][4] - The company has indicated that the pledge risk is under control, with no occurrence of forced liquidation or changes in actual control [4]

Summary of Key Points Core Viewpoint - The company, Yuanda Industrial Holdings Co., Ltd., has announced a guarantee for its subsidiaries to secure bank credit, with a total guarantee amount not exceeding 1.308 billion yuan, which is significant given the company's recent financial metrics [1][10]. Guarantee Overview - The company and its wholly-owned subsidiary, Yuanda Material Group Co., Ltd., have signed contracts with banks to provide guarantees for credit applications by subsidiaries, with specific amounts allocated to different banks [1][2]. - The total guarantee amount includes 360 million yuan to Agricultural Bank of China and 100 million yuan to Bank of Communications, among others [1][2]. Financial Metrics of Subsidiaries - Yuanda Oil Chemical Co., Ltd. reported a sales revenue of 306.47 million yuan and a net profit of 81.38 million yuan for the year 2024, with total assets of 892.70 million yuan and liabilities of 695.20 million yuan [4]. - Yuanda International (Hong Kong) Co., Ltd. achieved a sales revenue of 287.26 million yuan and a net profit of 35.51 million yuan for the year 2024, with total assets of 728.13 million yuan [5]. - Yuanda Changrui Resources (Zhejiang) Co., Ltd. reported a sales revenue of 20.73 million yuan and a net profit of 0.09 million yuan for the year 2024, with total assets of 22.31 million yuan [7]. Guarantee Agreement Details - The guarantees provided are joint liability guarantees, with a guarantee period of three years from the expiration of the main contract's debt performance period [8][9]. - The scope of the guarantees includes all principal debts, interest, penalties, and costs associated with debt recovery [9]. Board's Opinion - The board believes that the guarantees will support the subsidiaries' business development, help them access low-cost funding, and are in the best interest of the company and its shareholders [10]. - The financial risks associated with these guarantees are considered manageable, and the subsidiaries are deemed capable of repayment [10]. Cumulative Guarantee Amounts - The company has provided a total guarantee amount of 1,015.885 million yuan to its subsidiaries, which represents 495.25% of the company's audited net assets for 2024 [10][11]. - The company has also provided guarantees to entities outside the consolidated financial statements amounting to 850 million yuan, which is 36.18% of the company's audited net assets for 2024 [11].

Core Viewpoint - The company, Dizalpharma, is set to hold a collective performance briefing for the first half of 2025 on September 16, 2025, to discuss its operational results and financial status with investors [1][2]. Group 1: Meeting Details - The meeting will take place on September 16, 2025, from 15:00 to 17:00 [1][2]. - It will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website [1][2]. - The format of the meeting will be an interactive online session [2]. Group 2: Participation Information - Investors can submit questions from September 9, 2025, to September 15, 2025, via the Roadshow Center website or through the company's email [3]. - The company will address commonly asked questions during the briefing [3]. Group 3: Participants - Key participants include the Chairman and General Manager, Dr. Zhang Xiaolin, and the Secretary of the Board and CFO, Mr. Lv Hongbin, along with independent directors [2]. Group 4: Contact Information - For inquiries, investors can contact the Board Office via phone or email [3].

Core Points - The company, Wuxi Chison Medical Technology Co., Ltd., will hold a collective performance briefing for the medical device industry on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing aims to provide investors with a comprehensive understanding of the company's operating results and financial status for the first half of 2025 [1] - The event will be conducted in an interactive text format via the Shanghai Stock Exchange's online platform [2][3] Meeting Details - The meeting will take place at the Shanghai Stock Exchange Roadshow Center [2][3] - Key participants include the Chairwoman and General Manager, Mo Ruoli, along with other board members and the investor relations officer [2] - Investors can participate online and submit questions from September 10 to September 16, 2025, prior to the meeting [2][3] Contact Information - The company’s securities affairs department can be contacted at 0510-85271380 or via email at info@chison.com.cn for further inquiries [3]

Group 1 - The company will hold a collective performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted via video recording and online interaction at the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions from September 9 to September 15, 2025, before 16:00, through the Roadshow Center website or via the company's email [3][4] Group 2 - Key personnel attending the briefing include the Chairman and General Manager, LI SHENGFENG, and other board members and executives [2] - The company aims to address common investor concerns regarding its operational results and financial indicators for the first half of 2025 during the briefing [2][3] - After the briefing, investors can access the main content and updates through the Shanghai Stock Exchange Roadshow Center [4]

Group 1 - The company will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [1][2] - Investors can submit questions from September 10 to September 16, 2025, before 16:00, through the Roadshow Center website or via the company's email [3] Group 2 - Key participants in the briefing include Chairman Eric Gang Hu, General Manager and Secretary of the Board Qiu Zhiye, and Chief Financial Officer Wang Ling [2] - After the briefing, investors can view the meeting details and main content on the Shanghai Stock Exchange Roadshow Center [4]

Core Viewpoint - The company will participate in the 2025 semi-annual performance briefing for the biopharmaceutical and CXO industry on September 15, 2025, to address investor concerns and discuss its operational results and financial status for the first half of 2025 [1][2]. Group 1: Meeting Details - The meeting is scheduled for September 15, 2025, from 15:00 to 17:00 [2][3]. - The location of the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website: http://roadshow.sseinfo.com/ [2][3]. - The format of the meeting will be an online interactive session [2][3]. Group 2: Participation Information - Investors can participate in the meeting by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [3]. - Investors are encouraged to submit questions from September 8 to September 12, 2025, before 16:00, either through the Roadshow Center's "Pre-Question Collection" section or via the company's email [3]. - The company will respond to commonly asked questions during the briefing [3]. Group 3: Attendees - Key attendees include the Chairman Ye Jun, General Manager Guo Mingjie, Vice General Manager and Financial Officer Wu Yiming, Vice General Manager and Board Secretary Li Fangli, and Independent Director Liu Zhijie [2].

Group 1 - The company has adjusted its estimated daily related party transactions for the year 2025, increasing the total expected amount from 79.6 million yuan to include an additional 1.5 million yuan for sales to a related party [1][2][3] - The revised expected amount for sales of goods and services to Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd. has increased from 1 million yuan to 2.5 million yuan [1][3] - The adjustments were approved by the company's independent directors before being submitted to the board for review, ensuring compliance with relevant regulations [2][6] Group 2 - The company’s total expected related party transactions for 2025 include purchasing goods and services up to 2.6 million yuan, selling goods and providing services up to 75.3 million yuan, and renting assets and paying utility fees up to 1.7 million yuan [1][2] - The related party, Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd., has a registered capital of 12.6111 million yuan and is involved in the research, production, and sales of pharmaceuticals and medical devices [3][4] - The company confirms that the pricing for these transactions is based on market rates and does not harm the interests of non-related shareholders [5][6]

Core Viewpoint - The company, Shandong Dawn Polymer Materials Co., Ltd., is set to hold an online performance briefing for its 2025 semi-annual report to enhance communication with investors and provide a comprehensive understanding of the company's situation [1][2]. Group 1: Performance Briefing Details - The performance briefing will be conducted online, featuring Mr. Zou Yuanyong, the Deputy General Manager and Chief Financial Officer [1]. - The briefing is scheduled to take place on August 26, 2025, and will be accessible through the "Jing Roadshow" platform [1]. Group 2: Investor Engagement - The company is actively soliciting questions from investors ahead of the performance briefing to improve the effectiveness of communication [1]. - Investors can submit their questions until September 12, 2025, at 14:00 via a dedicated webpage [1].

Group 1 - The company will hold a half-year performance briefing on September 12, 2025, from 15:00 to 16:00 [1][2] - The briefing will be conducted via the "Suzhou High-tech Investor Relations" mini-program on WeChat, allowing for interactive communication [1][2] - Key company personnel attending the briefing include the Vice Chairman and General Manager, independent directors, and the CFO [2] Group 2 - Investors can submit questions in advance through provided contact methods, and the company will address common concerns during the briefing [2] - After the briefing, investors can access the main content and details of the meeting through the mini-program [2]